apid Communication ecreased Bladder Cancer Growth n Parous Mice

BJECTIVES To investigate the association between parity and exophytic bladder cancer growth in the UPII-SV40T transgenic mouse model of bladder cancer. ETHODS The UPII-SV40T transgenic mice express the simian virus 40 large T antigen specifically in the urothelium (driven by uroplakin II promoter) and reliably develop bladder cancer. UPII-SV40T transgenic female mice were either never bred (nulliparous; n 6) or placed in breeding pairs and allowed full-term pregnancies and lactation. Multiparous animals (n 5) had between 2 and 4 litters. UPII-SV40T transgenic male mice were sham-operated (intact; n 9) or castrated (n 8) at 24 weeks of age. Noninvasive, contrast-enhanced, flat panel detector-based, cone beam computed tomographic imaging of animals at 32 weeks of age permitted quantification of bladder cancer volumes. ESULTS Multiparous animals had significantly smaller bladder cancers than their nulliparous female (P .001) and intact male (P .007) counterparts but not different from castrated males. Bladder cancer volume in nulliparous females was significantly larger than castrated males (P .001) but not different from intact males. ONCLUSIONS These results suggest that pregnancy, parity, lactation, or a combination of these may play a protective role in bladder cancer by inhibiting tumor growth. This could be an important model system for studying the effects of pregnancy/lactation hormones on bladder cancer, which could lead to identification of additional risk factors of bladder cancer. UROLOGY 72: 470 – 473, 2008. © 2008 Elsevier Inc.

[1]  G. Sonpavde,et al.  Efficacy of selective estrogen receptor modulators (SERMs) in a murine xenograft model bearing human bladder cancer , 2005 .

[2]  A. Schatzkin,et al.  Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study , 2006, International journal of cancer.

[3]  L. Hilakivi-Clarke.  Estrogens , BRCA 1 , and Breast Cancer 1 , 2000 .

[4]  T. Sun,et al.  Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. , 1999, Cancer research.

[5]  Aimee M. Johnson,et al.  Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1 , 2008, BMC urology.

[6]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[7]  N. Tanahashi,et al.  Effects of sex hormones on oncogenesis in rat urinary bladder by N-butyl-N-(4-hydroxybutyl)-nitrosamine. , 1977, International journal of clinical pharmacology and biopharmacy.

[8]  G. Sonpavde,et al.  Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. , 2006, Cancer.

[9]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.

[10]  C. Lynch,et al.  Bladder cancer, parity, and age at first birth , 2004, Cancer Causes & Control.

[11]  J. Scott,et al.  Raloxifene: a selective estrogen receptor modulator. , 1999, American family physician.

[12]  E. Messing,et al.  Gender, racial and age differences in bladder cancer incidence and mortality. , 2004, Urologic oncology.

[13]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[14]  D. Michaud,et al.  Hormonal and reproductive factors and the risk of bladder cancer in women. , 2006, American journal of epidemiology.

[15]  Aimee M. Johnson,et al.  Early detection and measurement of urothelial tumors in mice. , 2006, Urology.